Introduction
============

Community-acquired pneumonia (CAP) is a leading disease associated with a high mortality and requiring hospitalization ([@b1-etm-0-0-4153],[@b2-etm-0-0-4153]). In the United States, \~4 million people are diagnosed with CAP annually, with \~600,000 of these patients requiring hospitalization ([@b3-etm-0-0-4153]). In Turkey, according to the 2014 health statistics by the Turkish Ministry of Health, pneumonia accounts for 2.6% of mortality cases ([@b4-etm-0-0-4153]).

It is not always possible to establish the disease etiology for patients with pneumonia ([@b5-etm-0-0-4153]). In addition, although the equipment required to identify the etiologic agent is available, isolation of the agent may take up to seven days ([@b6-etm-0-0-4153]). A review of the CAP literature in Turkey shows an identification rate of 21--62.8% ([@b5-etm-0-0-4153]). Holter *et al* ([@b7-etm-0-0-4153]) and Qu *et al* ([@b8-etm-0-0-4153]) reported that viral agent was present in \~1/3 of all pneumonias in Norway and China, respectively. In patients with CAP, a delay \>4-8 h in treatment results in an increased mortality rate ([@b9-etm-0-0-4153]). Pneumonia is initially treated with empiric therapy, since isolation of the agent is challenging and time-consuming. Two newly published studies have shown that viruses in CAP patients were detected as causative agents in 34% and 27.5%, respectively. ([@b7-etm-0-0-4153],[@b8-etm-0-0-4153]). In these studies, influenza and human rhinovirus were the most common causative agents. Other agents included parainfluenza viruses, respiratory syncytial virus, metapneumovirus, enterovirus and adenovirus ([@b7-etm-0-0-4153],[@b8-etm-0-0-4153]).

A new strain of Influenza A virus caused an outbreak of human infection in April 2009 in the USA and Mexico, and spread rapidly to other regions. This strain was classified as Influenza A H1N1 (H1N1) ([@b10-etm-0-0-4153]). Since 2009, this novel virus has been the most prevalent viral pneumonia agent among the respiratory viruses ([@b7-etm-0-0-4153]). The influenza A H1N1 infection exhibits a greater impact on populations \<65 years old than other seasonal influenza viruses ([@b10-etm-0-0-4153]). Pandemic H1N1 is primarily a mild, self-limiting upper respiratory tract illness, but unlike seasonal influenza, H1N1 leads to a more severe infection and high mortality rate in young adults ([@b11-etm-0-0-4153]). It was reported that 2--5% of confirmed cases in the USA and Canada, and 6% of cases in Mexico required hospitalization ([@b12-etm-0-0-4153]). The majority of hospitalized patients had underlying conditions such as cardiovascular disease, respiratory diseases including asthma and chronic obstructive pulmonary disease, auto-immune disorders, obesity, diabetes or cancer ([@b12-etm-0-0-4153]). In addition, secondary bacterial infections may be accompained by influenza pneumonia ([@b7-etm-0-0-4153]). Treatment with oseltamivir in H1N1 infections should be initiated within the first 48 hours ([@b13-etm-0-0-4153]). Therefore, it is necessary to ensure early diagnosis of viral pneumonias.

The present multicenter study retrospectively examined the clinical, demographic and prognostic characteristics of patients diagnosed with epidemic viral pneumonia in Turkey.

Patients and methods
====================

### Patients and viral pneumonia diagnosis

A total of 92 patients were included in the study. The male/female ratio was 42/50, and the mean age was 48.74±16.65 years. Patients were from 11 individual secondary and tertiary care hospitals located in various regions of Turkey and the study was performed retrospectively from January 2015 to April 2015. The patients had all been previously diagnosed with viral pneumonia. The patient files were retrospectively reviewed and included in the study. Viral pneumonia was diagnosed according to clinical and radiological examination results, and the exclusion of alternative causes. To confirm the diagnosis of viral pneumonia, nasopharyngeal, oropharyngeal and nasal swab specimens were placed into Virocult transport media (Medical Wire & Equipment, Wiltshire, UK), and transferred to the Virology Laboratory of the Ankara Refik Saydam Hygiene Institute (Ankara, Turkey) in accordance with the cold chain principles ([@b14-etm-0-0-4153]), and were evaluated using the quantitative polymerase chain reaction (qPCR) method assay as recommended by the World Health Organization ([@b15-etm-0-0-4153]). Following appropriate preparations, accepted laboratory samples were tested with PCR to detect the presence of influenza A/influenza B via targeting the conservative gene region of the influenza virus. A second PCR reaction was carried out using H1, H3 and H5 primers to identify the subtype of the influenza virus present in the samples. Based on the full genomic sequence of the recently-identified H1N1 virus, incoming samples were sequenced. Therefore, typing and genetic characterization of virus was provided.

All patients were treated with 150 mg/day of the antiviral therapeutic oseltamivir. Secondary bacterial infections may be accompained by influenza pneumonia; therefore patients additionally received intravenous fluoroquinolones or clarithromycin (1,000 mg/day), in combination with intravenous β-lactam antibiotics.

### Monitoring of viral pneumonia

The symptoms, medical history, radiological examination, hemogram levels, C-reactive protein (CRP) level (normal range: 0--5 mg/l) and biochemical parameters (such as sedimentation, urea, creatinine, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase) of the patients were recorded. Arterial blood gas values for those who required intensive care admission were also recorded. Furthermore, the following were obtained from the patient files: Relevant information from the day of presentation after the onset of symptoms, monitoring parameters \[such as arterial blood pressure, pulse rate, fever, and days spent in the intensive care unit (ICU)\] were recorded in the clinic and/or ICU, and the treatment administered following disease diagnosis.

### Statistical analysis

Data analysis was performed using the Minitab 14 statistical software (Minitab, Inc., State College, PA, USA). Descriptive statistics were performed to analyze patient characteristics ([Table I](#tI-etm-0-0-4153){ref-type="table"}). The Student\'s t-test and Chi-square test were performed to analyze quantitative data, assuming a normal distribution, and to analyze qualitative data, respectively. P\<0.05 was considered to be statistically significant. Prognosis was used as an outcome (response variable) to establish a binary logistic regression model, with '1' corresponding to alive, and '0' corresponding to mortality. Initially, the complete set of demographic variables and laboratory values that were potentially associated with mortality were included in the model. Following this, a backward-elimination approach was performed within a multiple explanatory variable logistic regression model in order to evaluate the model for potential confounding effects. In this model, the factors/covariates were removed individually in decreasing order of P-value until the remaining factors had a two-sided P value \<0.05. Following this, the Hosmer-Lemeshow test was performed to determine the goodness-of-fit.

The study was approved by the Ethics Board of the Abant İzzet Baysal University (Bolu, Turkey). The requirement for informed consent was waived by the Ethics Board due to the study\'s retrospective design.

Results
=======

### Patient characteristics and symptoms

Of the 92 patients that were included in the present study, 69 (75%) patients were unvaccinated against influenza. The demographic characteristics, main laboratory results and radiological findings of the patients are outlined in [Table I](#tI-etm-0-0-4153){ref-type="table"}. The most prevalent symptoms were a cough (87%) and a fever (63%). The duration between the onset of symptoms and presentation to the hospital was 5.51±3.27 days, and 18 patients (19.6%) had a history of contact with individuals complaining of upper respiratory tract viral infections. The prevalence of symptoms is depicted in [Table II](#tII-etm-0-0-4153){ref-type="table"}. No additional disorders were found in 56.5% of patients. The prevalence of comorbidities are shown in [Table II](#tII-etm-0-0-4153){ref-type="table"}.

### Clinical indications of pneumonia

Chest radiographies revealed bilateral patchy pneumonic infiltrates in 69.6% of patients. Chest computed tomography (CT) identified peripheral multiple patchy areas of ground glass density in 38 patients (41.3%). Bilateral alveolar-interstitial consolidations and ground-glass opacities were observed in five patients by chest X-ray and CT imaging ([Figs. 1](#f1-etm-0-0-4153){ref-type="fig"}--[5](#f5-etm-0-0-4153){ref-type="fig"}). From the laboratory findings, leukocyte count was found to be within the normal range, \>10,000/mm^3^, in 54 patients (58.7%). The lymphocyte count was found to be below the normal limit, at a median value of 1,000/mm^3^, in 34 patients (37%). The laboratory data are detailed in [Table I](#tI-etm-0-0-4153){ref-type="table"}.

The throat and nasal swab specimens of 37 patients with clinical and radiological findings suggestive of viral pneumonia were sent to the laboratory. Treatment was initiated on the same day. A total of 22 (59.4%) of these patients had H1N1, and 5 (12.5%) patients had influenza B. Patients with suspected viral pneumonia were administered the antiviral drug oseltamivir, on a dose of 150 mg/day, and monitored accordingly.

### Outcomes of patients admitted to the ICU

Of the 92 patients in total, 38 (41.3%) patients met the criteria for admission to the ICU. Of these patients, 20 (52.63%) were monitored with a mechanical ventilator, with a noninvasive mechanical ventilator (NIMV) being adequate for 10 (26.32%) of the patients. A smaller group of 8 (8.7%) patients were monitored with NIMV during weaning from mechanical ventilation. The length of stay in the ICU was 6.45±5.97 days (1--30 days), and the duration of mechanical ventilation (MV) was 5.06±4.69 days (1--18 days). A total of 12 (13.04%) patients did not survive treatment. Logistic regression analysis indicated that among the parameters potentially associated with mortality, current smoking increased the mortality risk 7.08-fold compared with non-smokers and ex-smokers (95% confidence interval: 1.81--27.67) (P=0.005). No significant relationship was found between mortality and other parameters, including age, gender, comorbid diseases, platelet count, lactate dehydrogenase (LDH) level, arterial blood oxygen level at the time of presentation and creatine kinase (CK).

Discussion
==========

The present study demonstrated that the majority of patients diagnosed with viral pneumonia were middle-aged individuals presenting with major symptoms of a cough, fever and shortness of breath. The patients displayed a rapid progression of patchy infiltrates in their chest radiographies and a large proportion required admission to the ICU. A total of 38 (41.3%) patients were monitored at the ICU, and 20 (52.63%) required MV. The rate of mortality was 13.04%. Active smoking caused a 7.08-fold increase in the mortality risk.

In the present study, the mean age was 48.74±16.65 years, with no significant difference in gender. A past study comparing patients with bacterial CAP and viral pneumonias found the mean age to be 60.0±20.2 years for bacterial CAP patients vs. 49.7±18.7 years for viral pneumonia patients ([@b16-etm-0-0-4153]). In a general study of patients with CAP, the mean age was 66 years, with a range of 52--78 years ([@b7-etm-0-0-4153]). Another study found that 90.3% of patients with H1N1 were younger than 65 years ([@b17-etm-0-0-4153]). In the present study, the mean age was found to be lower for viral pneumonia compared to that recorded previously for bacterial pneumonia ([@b5-etm-0-0-4153],[@b16-etm-0-0-4153]). However, the present results are consistent with the previously recorded mean ages of patients with viral pneumonia ([@b16-etm-0-0-4153],[@b18-etm-0-0-4153]).

A study including 1,088 cases performed in 2009 during the H1N1 pandemic reported that the clinical status of patients deteriorated rapidly; 31% required intensive care, mortality was higher in those \>50 years-old, overall mortality was 11% and the rate of comorbidity was 68% ([@b19-etm-0-0-4153]). Similarly, Gürgün *et al* reported that 25% of patients diagnosed with influenza pneumonia required intensive care ([@b16-etm-0-0-4153]), while Almirall *et al* found that the rate of ICU admissions was 7% in patients with bacterial CAP vs. 19.3% in patients with viral CAP ([@b20-etm-0-0-4153]). Furthermore, Rello *et al* reported an ICU admission rate of 62.5% in H1N1 pneumonia ([@b21-etm-0-0-4153]). For the patients of the present study, the rate of ICU admission was 41.3%. This higher rate relative to that documented for bacterial pneumonia suggests that patients with suspected viral pneumonia may require closer monitoring ([@b5-etm-0-0-4153]).

An analysis of several demographic and laboratory phenotypes (including age, gender, CRP level, sedimentation, urea, creatinine, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase and creatine kinase) associated with mortality indicated that active smoking increased the mortality risk 7.08-fold. Previously published studies on CAP have revealed that 72% of pneumonia cases requiring intensive care were predisposed by smoking ([@b22-etm-0-0-4153]). Similarly, smoking has been found to be a risk factor in patients requiring admission to the ICU for viral pneumonia ([@b23-etm-0-0-4153]). Cigarette smoke disrupts the pulmonary defense mechanism by reducing mucociliary clearance ([@b24-etm-0-0-4153]). This deterioration in the defence mechanism may be associated with the increased rate of mortality with pneumonia in current smokers. Although it is established that mortality is higher in patients admitted to the ICU, a direct association between active smoking and mortality in viral pneumonia remains to established. Previous analysis of the radiological imaging methods indicated that bilateral involvement was greater in viral pneumonias ([@b25-etm-0-0-4153]), while other studies found that radiological presentation varies substantially, and thus, has no predictive value in differential diagnosis ([@b26-etm-0-0-4153]). Similar to the results by Shiley *et al* ([@b25-etm-0-0-4153]), present results of the chest radiography and chest CT imaging revealed bilateral pneumonic infiltrates in 69.6 and 79.2% of patients, respectively.

The current study found that 69 (75%) patients were unvaccinated against influenza. This may be due to the proportion of young adults included in the patient group, or that only 26.09% of cases exhibited comorbidities. As viral pneumonias are thought to progress rapidly following the onset of symptoms ([@b21-etm-0-0-4153]), and the present study found a mortality rate of 13.04%, these results suggest that influenza vaccination should not be overlooked by individuals who have no contraindications for vaccination. In the present study, 1 out of 12 of the patients who did not survive were vaccinated against influenza.

Similar to previous studies, the current study found that the majority (59.4%) of viral swab specimens taken from patients with suspected viral pneumonia were positive for influenza A ([@b7-etm-0-0-4153],[@b8-etm-0-0-4153]). The patients from whom specimens where not requested consisted of those who had suspected viral pneumonia based on clinical, radiological and laboratory findings, however, lacked the growth of any other microorganisms. In clinical practice in Turkey, swab specimens from patients who are suspected to have viral pneumonia, are analysed only during the 'influenza season' (i.e., December-March). When cases of influenze are less prevalent, diagnoses are made according to clinical and radiological findings. Nevertheless, an association between early antiviral treatment and better survival has been demonstrated by previous studies ([@b19-etm-0-0-4153],[@b27-etm-0-0-4153]). In the present study, patients were treated with oseltamivir. Secondary bacterial infections may be accompained by influenza pneumonia ([@b7-etm-0-0-4153],[@b28-etm-0-0-4153]); therefore, patients additionally received fluoroquinolone or clarithromycin, in combination with intravenous β-lactam antibiotics.

The current study had a number of limitations. In January 2015, the cases of viral pneumonias were considered to be sporadic and not at an epidemic level. Therefore, specimens were not obtained from each patient to identify the strain types. By contrast, when increasing numbers of cases were reported by multiple centers, particularly in February and March 2015, specimens were collected from the patients to confirm the diagnosis of viral pneumonia. The present study was performed retrospectively and was multicentric; as such, some laboratory results could not be obtained from all patients.

In conclusion, viral pneumonia remains a major health problem during the winter period. In affected patients, the H1N1 virus is a potential etiologic agent. Therefore, H1N1 should be considered, particularly in patients presenting with symptoms of pneumonia. These include fever, shortness of breath and muscle pain during the influenza season, coupled with clinical characteristics, including high levels of CRP, LDH and CK, and radiological evidence of bilateral pneumonic infiltrates that progress rapidly. Smoking habits should be particularly questioned, due to findings of an association between active smoking and increased mortality. As viral pneumonia is associated with high mortality and the need for ICU admission, antiviral treatment should be rapidly initiated upon clinical suspicion of the disease. However, there is still no method to quickly isolate the pneumonia agent. Further research is required to elucidate the role of active smoking on pneumonia mortality. Additionally, further studies should be performed to identify a method for rapid and definite pneumonia agent isolation.

![Influenza A (H1N1)-positive viral pneumonia. Image shows a 49-year-old woman admitted to hospital with complaints of a cough and fever. (A) The posteroanterior chest X-ray and (B) thoracic computed tomography scan displayed bilateral patchy ground-glass opacities (arrows).](etm-13-04-1431-g00){#f1-etm-0-0-4153}

![Influenza A (H1N1)-positive viral pneumonia. Image shows a 43-year-old man admitted to the intensive care unit due to acute respiratory failure. (A) Bilateral alveolar-interstitial consolidations and ground-glass opacities (arrows) were observed by chest X-ray. (B) One month later, healing with fibrosis (arrows) was observed by chest X-ray.](etm-13-04-1431-g01){#f2-etm-0-0-4153}

![Influenza A (H1N1)-positive viral pneumonia. Image shows a 43 year-old man admitted to the intensive care unit due to acute respiratory failure. Bilateral alveolar-interstitial consolidations and ground-glass opacities (black arrows) were observed by (A) chest X-ray and (B) chest computed tomography imaging. (C) Bilateral minimally pleural fluid was also observed on chest computed tomography (blue arrows). One month later, (D and E) healing with fibrosis (white arrow) was observed and (F) pleural fluid had disappeared (red arrow).](etm-13-04-1431-g02){#f3-etm-0-0-4153}

![Influenza A (H1N1)-positive viral pneumonia. Image shows a 38-year-old man presented with a cough, dyspnea and fever. (A and B) The posteroanterior chest X-ray revealed rapidly progressing bilateral consolidation (arrows), despite treatment with antibiotics. (C and D) Bilateral alveolar-interstitial consolidations and ground-glass opacities (arrows) were observed by chest computed tomography imaging.](etm-13-04-1431-g03){#f4-etm-0-0-4153}

![Influenza A (H1N1)-positive viral pneumonia. Image shows a 55-year-old woman admitted to hospital with complaints of a cough, dyspnea and fever. Chest computed tomography imaging displayed bilateral alveolar consolidations (red arrows) and ground-glass opacities (black arrows).](etm-13-04-1431-g04){#f5-etm-0-0-4153}

###### 

Demographic and laboratory characteristics of patients.

  Variable                              n           \%
  ------------------------------------- ----------- -------
  Age (mean ± SD), year                 48.7±16.6   --
  Male/female                           42/50       --
  Smoking status                                    
    Non-smoker                          47          51.1
    Smoker                              18          19.6
    Ex-smoker                           27          29.3
  Duration of symptoms (median; days)   5.5         
    Past contact with upper             18          19.6
    respiratory viral infections                    
  Influenza vaccination                             
    No                                  69          75.0
    Yes                                 3             3.3
  Arterial blood gas (median)                       
    pH                                  7.43        
    PaO~2~ (mmHg)                       55.0        
    PaCO~2~ (mmHg)                      35.0        
    SaO~2~ (%)                          89.3        
  Laboratory values (median)                        
    Leukocytes (/mm^3^)                 6,484       
    Lymphocytes (/mm^3^)                1,000       
    Neutrophils (/mm^3^)                4,507       
    Platelets (/mm^3^)                  184,500     
    C-reactive protein (mg/l)           20.3        
    Sedimentation (mm/h)                35          
    Urea (mg/dl)                        23.7        
    Creatinine (mg/dl)                  0.88        
    Aspartate aminotransferase (IU/l)   36          
    Alanine aminotransferase (IU/l)     33          
    Lactate dehydrogenase (IU/l)        401.5       
    Creatine kinase (IU/l)              94.2        
  Chest X-ray                                       
    Consolidation                                   
    Bilateral                           64          69.6
    Unilateral                          23          25.0
    Pleural effusion                    3             3.3
  Chest tomography                                  
    Consolidation                                   
    Bilateral                           38          79.2
    Unilateral                          10          20.8
    Pleural effusion                    4             8.3
  Virology                                          
    H1N1 positivity                     22          59.4
    Influenza positivity                5           12.5
    Negative                            10          27.1

SD, standard deviation; PaO~2~, partial arterial oxygen pressure; PaCO~2~, partial arterial carbon dioxide pressure; SaO~2~, arterial oxygen saturation.

###### 

Distribution of symptoms and comorbid diseases in patients.

  Variable                                                           n    \%
  ------------------------------------------------------------------ ---- ------
  Symptoms                                                                
    Cough                                                            80   87.0
    Fever                                                            58   63.0
    Dyspnea                                                          54   58.7
    Malaise                                                          30   32.6
    Myalgia                                                          16   17.8
    Headache                                                         15   16.3
    Gastrointestinal^[a](#tfn2-etm-0-0-4153){ref-type="table-fn"}^   7    7.6
    Upper airway^[b](#tfn3-etm-0-0-4153){ref-type="table-fn"}^       7    7.6
    Chest pain                                                       6    6.5
    Hemoptysis                                                       2    2.2
    Hoarseness                                                       1    1.1
  Comorbidities                                                           
    None                                                             52   56.5
    Hypertension                                                     16   17.4
    Chronic obstructive pulmonary disease                            14   15.2
    Diabetes mellitus                                                11   12.0
    Asthma                                                           6    6.5
    Coronary artery disease                                          5    5.4
    Malignancy                                                       2    2.2
    Cerebrovascular disease                                          1    1.1

Nausea, vomiting, diarrhea

Sore throat, cold.
